Evidence map›Paper›PMID 39030487›Full record

ArticleBMC public health2024

"We chose PrEP because I wanted to be sure that this child my wife was going to conceive was indeed mine." Factors influencing the choice of safer conception methods and experiences with its use: a qualitative study among HIV sero-discordant couples in Zimbabwe.

Joelle M Brown, Petina Musara, Serah Gitome, Miria Chitukuta, Bismark Mataveke, Thandiwe Chirenda, Nyaradzo Mgodi, Prisca Mutero, Allen Matubu, Gift Chareka and 11 more

Abstract read
In one paragraph

Article in BMC public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Joelle M BrownDepartment of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA, USA. joelle.brown@ucsf.edu.
Petina MusaraUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Serah GitomeCentre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.
Miria ChitukutaUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Bismark MatavekeUniversity of Zimbabwe, Harare, Zimbabwe.
Thandiwe ChirendaUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Nyaradzo MgodiUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Prisca MuteroUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Allen MatubuUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Gift CharekaUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Charles ChasakaraUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Caroline MurombedziUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Tinei MakurumureMercy-Care Fertility Centre, Harare, Zimbabwe.
Carolyn Smith HughesDepartment of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA, USA.
Elizabeth BukusiCentre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.
Craig R CohenDepartment of Obstetrics, Gynecology & Reproductive Sciences, University of California San Francisco, San Francisco, CA, USA.
Stephen ShiboskiDepartment of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA, USA.
Lynae DarbesDepartment of Health Behavior and Biological Sciences, University of Michigan, Ann Arbor, MI, USA.
George W RutherfordInstitute for Global Health Sciences, University of California San Francisco, San Francisco, CA, USA.
Z Michael ChirenjeDepartment of Obstetrics, Gynecology & Reproductive Sciences, University of California San Francisco, San Francisco, CA, USA.
Felix MhlangaUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.

Funding

UZ-UCSF CTUUM1AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ZVAVAHERA MIKE CHIRENJE, LYNDA STRANIX-CHIBANDA · 2012 to 2026
$75.9M
Impact and Cost-effectiveness of Safer Conception Strategies for HIV PreventionK01MH100994 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BROWN, JOELLE MORGAN · 2013 to 2017
$893k
NIAID NIH HHS UM1 AI069436NIMH NIH HHS K01 MH100994
6 · The paper itself

Abstract

backgroundSafer conception services are needed to minimize HIV transmission among HIV sero-discordant couples desiring pregnancy. Few studies have evaluated the choices couples make when they are offered multiple safer conception methods or real-world method acceptability. This paper addresses an important knowledge gap regarding factors that influence the choice of safer conception methods, couples' actual experiences using safer conception methods, and why some couples switch safer conception methods.

methodsBetween February and June 2019, we conducted semi-structured in-depth interviews among 14 men and 17 women, representing 17 couples who exited the SAFER study-a pilot safer conception study for HIV sero-discordant couples in Zimbabwe that offered couples a choice of ART with monthly viral load monitoring (ART/VL), oral PrEP, vaginal insemination, and semen washing. All couples in SAFER had used at least two safer conception methods.

resultsWe found that safer conception method choice often centered around a desire for intimacy, condomless sex, and certainty in the conception process, particularly for men. Method-related attributes such as familiarity, perceived ease of use, side effects, and perceived level of effectiveness in preventing HIV and achieving pregnancy influenced method choice, switching, and satisfaction. Concerns were expressed about each safer conception method and couples were willing to try different methods until they found method(s) that worked for them. The majority of participants reported having positive experiences using safer conception, especially those using ART/VL + PrEP, citing that they were able to attempt pregnancy for the first time with peace of mind and experienced joy and satisfaction from being able to achieve pregnancy safely.

conclusionsThe differences in method preferences and experiences voiced by participants in this study and in other studies from the region point to the importance of having a variety of safer conception options in the service delivery package and addressing concerns about paternity, intimacy, and method-related attributes to enable HIV sero-discordant couples to safely achieve their reproductive goals.

Indexed as

HIV InfectionsPre-Exposure ProphylaxisQualitative ResearchAdultChoice BehaviorFemaleFertilizationHIV SeropositivityHumansInterviews as TopicMaleMiddle AgedPilot ProjectsPregnancyYoung AdultZimbabweARTHIV-discordant couplesHIV preventionLMICPrEPSafer conceptionSemen washingsub-Saharan AfricaVaginal inseminationZimbabwe

Identifiers

PMID39030487
PMCPMC11264618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.